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Abstract

Introduction

Several inhibitors of the arachidonic acid-metabolizing enzyme, 5-lipoxygenase reduce proliferation of hematopoietic and non-hematopoietic cells and cell lines and
some cells undergo limited differentiation. Cells were
cultured from patients with chronic myelogenous leukemia in "blast" crisis with the selective inhibitor of 5lipoxygenase,SC41661A[3-{3 ,5-bis(l, 1-dimethyl)-4-hydroxyphenyl}hiol]-N-methyl-N-[2-(2-phridinyl-propanamide)]. Cells cultured for 3 to 5 days with 40 µM
SC41661A exhibited reduced cellular numbers along
with ultrastructural changes and DNA laddering characteristic of apoptosis. Similar culture conditions reduced
proliferation of U937 monoblastoid cells. In U937 cells,
the ultrastructural features of apoptosis were not observed at 72 hours, when DNA laddering was present
and cell numbers were reduced, but was present after
144 hours of culture. Dissociation between certain morphologic and biochemical sequelae of apoptosis has been
described in other systems. These observations are of
interest since the induction of apoptosis in dividing
chronic myelogenous leukemia (CML) cells by a noncytotoxic agent suggests paradigmatically new sites for
therapeutic intervention.

Myelogenous leukemia cells from patients and the
HL60 myelomonocytic and U937 monoblastoid cell lines
express the arachidonic acid-metabolizing enzyme, 5lipoxygenase [2]. This enzyme forms the hydroperoxy
and hydroxy intermediates, 5-HPETE, 5-HETE, and
leukotriene A4, leading to LTB4 (via LT4A hydrolase),
LTC4 (by LTC4 synthetase) and LTD4 (due to gammaglutamyl-peptidase), which can be subsequently cleaved
by various dipeptidases to yield LTE4. While most of
the biological effects of leukotrienes have been identified
in studies of immune function and smooth muscle contraction, a role in modulating proliferation of at least
some types of cells is a distinct possibility. Malignant
cells from patients with chronic myelogenous leukemia
synthesize excess amounts of leukotriene C4 [20].
Patients with myelogenous leukemia usually can be
maintained for some time with several forms of therapy,
but eventually the disease recurs and proliferating leukemia cells appear in the circulation. These cells are
unresponsive to agents as employed previously and can
be refractory to new therapy [9].
In the present study, we observed the induction in
vitro of apoptosis in chronic myelogenous leukemia
(CML) cells from paJients in "blast" crisis by a selective
non-cytotoxic inhibitor of 5-lipoxygenase [3, 10],
SC41661A [3-{3 ,5-bis(l, 1-dimethyl)-4-hydroxyphenyl}
thiol]-N-methyl-N-[2-(2-phridinyl-propanamide) }Jssociated with abortive attempts at expression of a differentiated function. While the mechanism of this response
is unknown, the ability to access an apoptotic pathway
inherent in myelogenous leukemia cells that have escaped first and often second-line therapy by a non-cytotoxic agent suggests future sites for therapeutic intervention.

Key Words: Leukemia, apoptosis, programmed cell
death, 5-lipoxygenase inhibitor, SC41661A.

• Address for Correspondence:
Ken. M. Anderson
Section of Medical Oncology
Departments of Biochemistry and Medicine
Rush Medical College
Chicago, IL 60612, USA
Telephone number: 312-942-6423
FAX number: 312-942-3192

Materials and Methods
Myelogenous leukemia cells from patients in blastic
crisis or U937 monoblastoid cells were maintained in
suspension culture by serial dilution every 3 to 4 days
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Figure 1. Control cells from a patient with CML in
blastic crisis. Bar = 2 µm.

Table 1. Effect of SC41661A on the 4 hour incorporation of 3H-thymidine (cpm ± standard deviation, SD)
into DNA of peripheral blood cells from patients with
CML in blastic crisis and into U937 monoblastoid cells.
N (number of samples) = 4 for each data point. Representative examples are presented. More extensive data
are presented in references [3, 4].
CML cells

U937 cells

2063 ± 196

10406 ± 296

20µM

1743 ± 219

4728 ± 322

40 µM

1324 ± 386

3673 ± 640

80 µM

525 ± 40

233 ± 26

Control

Figure 2. Apoptotic cells with extensive cytoplasmic
vacuolation and several others with extensively condensed chromatin with little residual cytoplasm. One
cell with marginated chromatin may represent a necrotic
cell. Bar = 2 µm.

sections examined with either a Siemens's 101 or a
100 ex TEM.
DNA was isolated with a DNA/RNA isolation kit
(United States Biochemical Co, Cleveland, OH) according to the accompanying instructions.
Cells were
centrifuged, washed and lysed with lysis buffer. After
adding the extraction buffer, the aqueous phase was
transferred to another tube and sodium acetate and isopropanol used to precipitate DNA. DNA was resuspended in TE buffer and incubated with DNase-free
RNase at 40°C for 1 hour. Samples (2-5 µg DNA each)
were electrophoresed on O.8 % agarose gels containing
ethidium bromide (0.5 µgfml gel) at 70-90 volts for 1.5
to 2 hours, bands visualized with ultra-violet light and
photographed with a Polaroid camera.
Work in progress employed an Apoptag kit from
Oncor, Gaithersburg, VA.

SC41661A

Table 2. The effect of 40 µM SC41661A on cell numbers after 5 days of culture (x 10·4/ml). N = 2. Representative experiments are presented and more extensive
data are presented in references [3, 4].
CML cells
Control

1.25 ± 0.34

SC41661A

0.04

±

0.03

U937 cells
66.9

± 9.2

27.4 ± 6.8

Results

with RPMI (Rosewell Park Memorial Institute, Buffalo,
NY) 1640 medium containing 5 % fetal bovine serum
(FBS; U937) or 10% FBS (CML), 24 mM HEPES {N(2-hydroxyethyl) piperazine-N' (2-ethylsulfonic acid)},
2 mM glutamine, 50 µgfml streptomycin and 50 units/
ml penicillin [17]. Before culture, cells from patients
were first purified on Ficoll gradients. Cell lines were
treated in log phase with 40 µM SC41661A in dimethylsulfoxide (DMSO; 1 µI/ml medium) after a 1:2 split
with medium for 24 hours; in some experiments, incorporation of 3H-thymidine was measured after 4 hours, in
others cells were cultured for an additional 48 to 120
hours before samples were taken for cell counts and
DNA electrophoresis.
Transmission electron microscopy (TEM) was performed according to conventional procedures including
fixation in glutaraldehyde (2.5 % in cacodylate buffer,
pH 7 .4) containing 4 % sucrose for 2 hours at room temperature [1]. Subsequently they were washed in buffer,
post-fixed with 1 % osmium tetroxide for 1 hour, rinsed
in buffer, stained for 1 hour in uranyl acetate, dehydrated with increasing concentrations of ethanol and
propylene oxide and embedded in epon/araldite. Grids
were stained with Reynold's lead and uranyl acetate and

SC41661A reduced the proliferation of CML blast
cells from patient's peripheral blood and of U937 monoblastoid cells in a concentration-dependent manner
(Table 1). These results are typical of those reported in
ref. [3, 4]; a lesser number of studies of the myeloblast
HL60 cell line with similar results are in progress (results not shown). The concentration of SC41661A employed was 1 to 2 times the IC 50 which inhibits PMN 5lipoxygenase activity [15]. Uptake of trypan blue at 4
hour was unchanged in control and experimental groups
(not shown). SC41661A is not considered to be cytotoxic [3, 4, 10, 15]. Cell counts after 3 or more days
were greatly reduced in drug-treated cultures (Table 2;
results are representative of additional experiments
reported in ref. [3, 4]).
Aliquots of CML cells cultured for 5 days with
SC41661A were removed for cell counts, viability and
transmission electron microscopy. Over half the cells
stained with trypan blue and cellular debris was present.
There was little evidence of apoptosis in control
CML cells (Fig. 1) and only occasional (less than several percent) cells exhibited structural changes consistent
with that process. SC41661A-treated cultures contained
50 percent or more cells exhibiting features of apoptosis
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Figure 3. An apoptotic cell with crescent-shaped condensed chromatin, another cell with extensive cytoplasmic vacuolation and little nuclear change evident. Bar

(Figs. 2-7). These included shrunken cells containing
typical nuclear apoptotic changes of condensed chromatin (Fig. 2) progressing to crescent-shaped accumulations
in some cells and globular accretions in others (Figs. 3
and 4). Increasingly extensive cytoplasmic vacuolation
occurred, some vacuoles representing what are interpreted as developing primary granules (Fig. 6). These represent differentiated structures consisting of vesicles
containing inactive degradative enzymes related to immune defence and characteristic of more mature granulocytes [6]. In some cells, precipitated chromatin appeared to leak into the residual cytoplasm after dissolution of the nuclear membrane (Fig. 6), compared with
other end-stage cells in which elements of chromatin remained attached to the nuclear membrane (Fig. 7).
Generally mitochondria were well preserved until later
stages of the process, when a variety of pycnotic fragments remained. In some cells, cytoplasmic vacuolation
was more extensive than nuclear changes (Figs. 2 and
3). Either other regions of their nuclei with apoptotic
changes were missed in the sectioning or such changes
were absent. Other cells apparently remained unaffected
by the drug (Figs. 4, 5, and 7). Many of the apoptotic
cells were in the later stages of dissolution when changes
of necrosis may be present.
One of a number of samples of CML cells from patients in blastic crisis cultured for 3 days with 40 µ.M
SC41661A and examined for DNA laddering is presented in Figure 8A. Lower molecular weight multiples of
DNA are present in this and in other comparable samples (not shown). We believe that laddering in the presence of SC41661A follows cessation of DNA synthesis,
so that susceptible cells either were in or enter a proliferative stage of the cell cycle which is inhibited by the
drug. Presently too few samples are available to definitely correlate the extent of proliferation as judged by
the percentage of blast cells and DNA laddering.
Several ultrastructural studies of U937 cells cultured
for 3 days with SC41661A have been done [e.g., 4].
Cytoplasmic or nuclear changes consistent with apoptosis
were not seen. More recently U937 cell_scultured with
SC41661A for 120 hours were found to exhibit nuclear
and cytoplasmic ultrastructural changes consistent with
apoptosis (work in progress, not shown).
Although ultrastructural studies of U937 cells cultured for 72 hours provided no evidence of necrosis or
apoptosis, DNA laddering was sought, employing 0.8 %
agarose gel electrophoresis and staining with ethidium
bromide (Fig. 8B.). U937 cells cultured with 40 µ.M
SC41661A for 3 days and compared with the DMSO
(vehicle) control exhibited DNA laddering consistent
with apoptosis in preparations in which cell numbers
were reduced compared with controls. When analyzed
with the Apoptag kit that identifies free 3 '-OH termini

= 2 µ.m.
Figure 4. An apoptotic cells with extensively condensed
chromatin, portions of which appear to be invaded by
cytoplasmic vacuoles. Bar = 2 µ.m.

of DNA, intense brown staining indicating these free
termini was present in nuclei of SC41661A-treated U937
cells with lesser staining of their cytoplasm, consistent
with the presence of DNA at that site (not shown, work
in progress). These results will be presented in a
subsequent communication.

Discussion
Discrepancies between characteristic morphologic
changes of apoptosis and DNA laddering have been described [7, 8, 11, 13]. IfDNA degradation is not extensive with the generation of oligosomes, laddering may
be absent in the presence of typical nuclear morphologic
changes [13]. In studies of embryonic systems, extensive cytoplasmic changes consistent with apoptosis have
been noted in the absence or a delayed presence of nuclear chromatin changes [7, 11, 22]. Features of both
necrosis and apoptosis may occur in different cells or in
the same cells and necrotic changes may be present as
an end stage of apoptosis. In addition, DNA laddering
has been reported to occur in cells undergoing necrosis
[8]. These variations depend upon the system studied
and conditions employed [5].
The kinetics of apoptosis, in some systems occurring from 20 minutes to perhaps an hour and the percent
of cells involved before or during this interval will determine if apoptotic cells are detected by morphology,
DNA laddering, or both. Apoptosis of only several percent of cells in a population can be sufficient to produce
DNA laddering. Whether cells from all or only some
stages of the cell cycle can be induced to access an
apoptotic program also depends upon the system studied
[16]. The rate at which high molecular Weight DNA is
degraded to oligomers should determine the ability to
detect apoptosis by these means. A prolonged half-life
of "nicked" high molecular weight DNA should favor
"capping" or other large scale DNA accumulations [13],
and characteristic nuclear DNA changes should be more
readily detected by electron microscopy, as seems to be
the case with CML blast cells. The presence of cytoplasmic changes consistent with apoptosis without typical
nuclear changes [7, 11, 22] suggests that components of
678
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Figure 7 (above). End stage of apoptotic cell dissolution with residual nuclear chromatin bodies. Bar = 2 µm.
·---------------------------------------------------------------------------------------------

provided by the clinician may have been drawn before
institution of new and possibly more successful therapy,
or at some time thereafter. Following chemotherapy or
radiation, apoptosis is a major mechanism of cell killing
and apoptotic cells could be present in the control samples from effectively treated patients. These factors can
complicate interpretation of these studies and may be the
reason for some DNA laddering in control samples. An
absence of actively proliferating cells may account for
any lack of DNA laddering in drug-treated cultured
cells, but this point needs to be examined with a larger
number of samples containing differing percentages of
replicating CML cells.
We now take up the issue of a proposed mechanism
for these results. Do we believe that inhibition of 5lipoxygenase by concentrations of a selective inhibitor
that are 1 to 2 times the IC 50 of the enzyme in mature
granulocytes is responsible? It can be suggested that one
or more products of 5-LP0x serve as an autocrine or
paracrine growth factor, thereby expressing anti-apoptotic activity, or modulate the activity of such agents.
There are precedents for this, since leukotriene products

Figure 5 (on the facing page). Apoptotic cells with
what appear to be swollen developing primary granules,
a measure of differentiation. Bar = 2 µm.
Figure 6 (on the facing page). Apparent dissolution of
the nuclear membrane with release of condensed chromatin into the remaining cytoplasm. Bar = 2 µm.
the apoptosis "program" can be dissociated and individually activated. Some of these variations may depend
upon karyotypic changes in the leukemia cell population,
with development of progressively more aneuploid chromosomes determining some of their phenotypes. If during apoptosis affected cells exhibit some indeterminate
marginated clumping of chromatin, swelling of the cytoplasm and its organelles with flocculent densities
appearing within mitochondria, these changes would indicate accompanying necrosis which could confound the
interpretation.
Most patients in blastic crisis have been on a maintenance therapy that has become unable to control the
disease. Depending upon circumstances, the sample
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A

B

Figure 8. DNA laddering of CML blast cells (A, at left) and of U937 cells (B, at right) cultured with 40 µM
SC41661A for 48 and 120 hours, respectively. D: DMSO control, middle lanes; SC: SC41661A, left lanes; DNA
standard: lambda Hin dIII from 23.1 to 0.6 kB (faint lower band), right lanes.

have been reported to serve the latter function [reviewed
in ref. 2]. However, suramin, employed in the treatment of metastatic prostate cancer provides an instructive cautionary example. Originally reported to inhibit
the interaction between epidermal growth factor and its
receptor, more recently it was also shown to impair
mitochondrial oxidative metabolism, prqviding a dual inhibitory effect on cellular proliferation [18]. It would
not be surprising if besides inhibiting 5-LP0x, which is
expected at the concentrations of SC41661A we employ
[15], additional biochemical events may occur that contribute to suppression of proliferation and induction of
apoptosis [15]. Originally Wickremasinghe et al. [21]
reported that MK866, a unique inhibitor of 5-LP0x
"tethering" to membranes (required for enzyme function)
did not reduce proliferation of cells known to contain 5LP0x, while other inhibitors of the enzyme that included
oxidation/reduction agents were able to inhibit proliferation of cells in which 5-LP0x was considered to be absent. However, subsequently they reported that MK866

inhibited proliferation of CML cells from 40 % of the patient samples studied, indicating that replication of CML
cells in this large subset was dependent upon functional
5-LP0x activity [14].
It is certainly possible that SC41661A at 40 µMinhibits this subset of replicating CML cells because of its
anti 5-LP0x activity, but in addition reduces the rate of
proliferation of the other 60 percent of CML cells by
additional mechanisms yet to be identified. Cells apparently unaffected by the drug may not have been cycling,
which may be a prerequisite for its channelling of the
cells into apoptosis. Antitumor effects of 5-LP0x have
been examined in at least two in vivo studies. Nafazatrom (Bay q 6575) (at 0. 8 mg/kg) inhibited the growth
of B16 melanoma cells in nude mice by 90 percent [12],
while SC41661A at 1.15 mg/mouse i.p. protected nude
mice from OVCAR human ovarian carcinoma cells [10]
without cytotoxic effects on the animals. SCIO (severe
combined immunodeficient) mice that receive human
CML cells intravenously exhibit a disease mimicking
682
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are characterized by strongly clustered or condensed
chromatin, in most images presented in the paper late
apoptotic features appear. How could the authors explain this behaviour? Why did you not see typical
"early" apoptotic patterns long described in the literature?
Authors: We agree that many of the apoptotic changes
in the CML cells are relatively late; the most likely
reason why we did not see early changes was the choice
of 120 hours of drug treatment before isolation of cells
for electron microscopy. It may be that accession of
apoptosis is cell cycle-dependent and cells are only
gradually accumulated in the appropriate (S?) phase of
the cycle prior to "exit" into apoptosis. This answer to
this question is being studied with U937 cells. The use
of CML blast cells is more difficult due to (a) the relative infrequency of samples, and (b) requirement for
ancillary growth factors such as IL3 and GM-CSF to
achieve maximum in vitro cell replication which, due to
their cost were not used.
The distinction between middle to late apoptosis and
its end-stage when secondary necrosis can be present is
not always easy to make. This is why, ideally, as many
distinct features of the process, morphologic, biochemical and cell-biological/functional, as can be adduced to
support the claim should be accumulated. The concept
of apoptosis, whether it is distinct from programmed cell
death, the appearance of what seems to be laddering of
DNA from cells induced to undergo necrosis [8], the
separation of DNA events in apoptosis from attempts at
conservative DNA replication, and DNA repair reactions, have not been studied extensively, at least not all
in the same system. Whether induction of apoptosis is
cell type-dependent, inducible from all or only from certain stages of the cell cycle, which protooncogenes, P53,
bcl-2, C-myc, C-fos, the RB gene participate in the various systems studied have not been coordinated into a
common scheme. It is also true that cells induced to undergo necrosis by several means can exhibit "classic"
DNA laddering [8]. For these and other reasons, a
"final" common definition of "apoptosis" has not yet
been developed. Since considerable variation among afferent signalling systems have been and, possibly less
likely the efferent effector pathway(s) will be found,
differences in detail among various pre and post-embryonic types of cells may preclude a common definition.

Discussion with Reviewers
A. Liepins: In the text you say: "SC41661A-treated
cultures contained 50 percent or more cells exhibiting
features of apoptosis (Figs. 2-7)"; what are the "features
of apoptosis"?
Authors: Generally, it is agreed that cells undergoing
apoptosis decrease in size, nuclear changes of unusual
condensations of chromatin occur, followed by intemucleosomal scission and release of oligomeric nucleosomal arrays. Cytoplasmic "apoptotic" vesicles appear but
generally, organelles such as mitochondria are relatively
unaffected until later in the process. Phagocytosis of affected cells and cell remnants occurs in vivo; in vitro,
without exposure to scavenger cells, disruption also occurs with release of vesicular material at times containing residual nuclear chromatin. As mentioned below,
programmed cell death occurring in embryonic systems
need not express all of these features [7, 8, 11, 13, 22].
A. Liepins: In the text you also say: "Increasingly
extensive cytoplasmic vacuolation occurred, some vacuoles representing what are interpreted as developing primary granules (Fig. 6)"; what are "primary granules"?
Authors: "Primary granules" normally begin to appear
in the cytoplasm of leukocytes during very early differentiation, and structures that fulfill this description were
seen in SC41661A-treated CML cells. When fully differentiated, such bodies contain various degradative enzymes used in the host defence against bacteria and
other engulfed foreign bodies. Please see reference [6]
for further information about these structures.
E. Falcieri: Why did you use 4% sucrose in the fixative? Can you exclude an osmotic effect on the cell?
Authors: Use of 4% sucrose in the fixative is intended
to avoid osmotic effects and is a fairly standard
technique in a number of laboratories.
E. Falcieri: It is well known that frequently the apoptotical process is followed by a "secondary necrosis".
This is characterized by a progressive hydration of
cytoplasm and organelles, with initially minimal nuclear
involvement. Plasma membrane and organelle disruption successively appear, allowing the lysosomal content
to leak out into the cytoplasm. In the apoptotic cell undergoing necrosis, only apoptotic nucleus can be recognized in the final stage. If assumed that apoptotic cells

E. Falcieri: How do you interpret those cells with cytoplasmic alterations but without evident nuclear changes?
Authors: A number of cells exhibited cytoplasmic
changes without evident nuclear alterations. That may
have been due to sampling and the manner in which
cells and their nuclei were sectioned. Alternately, in
some aberrant transformed cancer cells, the agent em-
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ployed might activate pre or post-nuclear events which
bypass that organelle, leading to "downstream" cytoplasmic apoptotic events, as suggested to occur in certain
forms of programmed cell death without early nuclear
changes. Conceivably, the karyotypic changes in chronic leukemic cells undergoing blastic crisis "uncouple"
some of the nuclear and cytoplasmic events observed in
apoptosis of non-transformed cells with normal karyotypes. Possibly relatively undifferentiated cells utilize a
"programmed cell death" pathway more akin to cell
death occurring in some embryonic systems. This is an
interesting question worth more thought.

was just not evident in the sample studied. Is less than
5 % consistent with generally accepted numbers in
leukemic cell cultures.
Authors: In control samples, we did not find a significant number of morphologically apoptotic cells (i.e.,
more than several percent, a "rare" cell was seen).
Faint DNA laddering could at times be seen in some cultured control samples but less than that from treated
samples exhibiting reduced numbers of cells. It has
been reported that several percent of apoptotic cells in a
population is sufficient to yield DNA banding. In other
words, it depends upon the clinical setting and a priori,
no rules are guaranteed. If patients have recently been
effectively treated, significant apoptosis might be expected; if they are in true blastic crisis with major proliferation of blast forms, spontaneously apoptotic cells may be
"lost" among the dividing forms unless their frequency
is augmented by treatment. Non-dividing CML cells
may not be susceptible to SC41661A-induced apoptosis.

M. Rubenstein: No biochemical markers such as the
amount of bcl-2 protein or mRNA are used, nor is end
group analysis using 3' terminal transferase labelling of
fragmented DNA.
Authors: Bcl-2 protein is not a general "marker" for
apoptosis, and for some types of cells, does not seem to
be involved in the process. In other systems, it may
retard or even prevent the process, but it is not thought
to be a universally active antiiapoptotic agent in all types
of cells. Studies with an end-labelling kit have been
performed and will be reported separately.

J.A. Kellen: In connection with Table 2 you say in the
text: "... results are representative ... ". What is
"representative"? Are these electron micrographs of the
most characteristic and typical areas and samples or are
they a typical average findings (from how many scans)?
Authors: "Representative" electron photomicrographs
include areas from apoptotic cells selected by an experienced electron microscopist that characterized the majority of the apoptotic cells observed. As mentioned, other
cells did not exhibit typical nuclear changes while presenting cytoplasmic fmdings consistent with apoptosis
and a few cells appeared to be unaffected by the drug
(discussed above). Whether the former represents programmed cell death in which extensive nuclear changes
are not present, at least not early in the process, is
unclear. Cells that appeared to be unaffected by the
agent may never have been in cell cycle, which we believe but have not demonstrated, may be a requirement
for SC41661A-induced CML cell apoptosis. Possibly
malignantly transformed CML cells, in which normal
differentiation is "blocked", express a more embryonic
form of "programmed" cell death as a dysfunctional
phenotype, as suggested above.

J.A. Kellen: ... However, in order to consider in vivo
studies, the effect of SC41661A could (and should) be
tested by flow cytometry of control and treated cell
cultures ( ... such as in Telford et al., J. Immunolog.
Methods, 172, 1-16, 1994).
Authors: Flow cytometry is certainly another means of
measuring DNA degradation. For some studies, especially those of the cell cycle susceptibility to apoptosis-inducing agents, use of the technique is ideal and
such studies are in progress with U937 cells.
J.A. Kellen: Perhaps an indication as to the mechanism(s) of multiple drug resistance (MDR) would be
appropriate in the Introduction.
Authors: We do not believe that discussion of multiple
drug resistance is indicated for this paper. Resistance to
drug-induced apoptosis, as distinct from drug resistance
due to MDR may represent one of the numerous forms
of "drug resistance". No studies of MDRl protein or
RNA synthesis were performed. Reasons why apoptosis
is readily induced in some and not in other types of cancer is a large! y unknown area of study, since the afferent
and efferent signal transduction pathways and effector
molecules for these events often differ among systems
studied and generally are not well defined.

I.D. Bowen: The authors should note that other investigators have discovered inconsistency between the morphological symptoms of apoptosis and the incidence of
DNA ladders (Bursch et al., 1992; Zakeri et al., 1993)
to the extent that DNA laddering is being questioned as
being diagnostic for apoptosis (Bowen, 1993).
Authors: The papers of Collins et al. (1992), Gershenson and Rotello (1992), Bowen (1993), and Zakeri et al.
(1993) discuss these more recent findings and their interpretation. Apoptosis or programmed cell death in can-

J.A. Kellen: In the text you say "There was little evidence of apoptosis in control CML cells (Fig. 1) ... " by EM! Obviously, there must be some apoptosis, but
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cer cells may present special problems of interpretation.
Malignantly transformed cells such as CML or
U937 cells in some sense "revert" to more (or are developmentally incapable of maturing from) "primitive" differentiation states in which apoptosis may not recapitulate the typical findings reported for mature cycling or
terminally differentiated cells. Programmed cell death
without typical DNA laddering (or with delayed laddering) may represent an earlier "precursor" form of nonnecrotic cell destruction in developmentally arrested
malignantly transformed cells. Whether various afferent
or efferent pathways involved in either process can be
accessed by non-cytotoxic means could be of considerable interest to those wanting to modify the biology of
cancer cells.

J.A. Kellen: In Table 2, surely "(x 10-4 /ml)" means
10,000 cells/ml and should read lo4/ml.

Authors: In the biochemical literature, a value of
10,000 generally is represented in tabular form as, e.g.,
(cpm x 10-4). Thus, 12.0 stands for 120,000 x 10-4 =
12.0.
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